Sobi snaps up gout drug in $950M deal for startup Arthrosi

Sobi is acquiring Arthrosi, a startup, for $950M to obtain a promising gout drug. Sobi claims the drug could become the "therapy of choice" for individuals experiencing persistent gout symptoms despite initial treatment.